Page last updated: 2024-10-26

etodolac and Condition, Preneoplastic

etodolac has been researched along with Condition, Preneoplastic in 3 studies

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.

Research Excerpts

ExcerptRelevanceReference
"Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions."6.75Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. ( Deguchi, H; Enomoto, S; Fujishiro, M; Ichinose, M; Iguchi, M; Inada, K; Inoue, I; Maekita, T; Mukoubayashi, C; Nakamura, Y; Oka, M; Takeshita, T; Tamai, H; Tsukamoto, T; Ueda, K; Utsunomiya, H; Yanaoka, K; Yoshimura, N, 2010)
"Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions."2.75Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. ( Deguchi, H; Enomoto, S; Fujishiro, M; Ichinose, M; Iguchi, M; Inada, K; Inoue, I; Maekita, T; Mukoubayashi, C; Nakamura, Y; Oka, M; Takeshita, T; Tamai, H; Tsukamoto, T; Ueda, K; Utsunomiya, H; Yanaoka, K; Yoshimura, N, 2010)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yanaoka, K2
Oka, M2
Yoshimura, N1
Deguchi, H1
Mukoubayashi, C1
Enomoto, S2
Maekita, T1
Inoue, I1
Ueda, K1
Utsunomiya, H2
Iguchi, M1
Tamai, H2
Fujishiro, M1
Nakamura, Y1
Tsukamoto, T2
Inada, K2
Takeshita, T1
Ichinose, M2
Yamamoto, K1
Kitayama, W1
Denda, A1
Morisaki, A1
Kuniyasu, H1
Inoue, M1
Kirita, T1
Magari, H1
Shimizu, Y1
Tomeki, T1
Arii, K1
Nakata, H1
Tsutsumi, Y1
Tatematsu, M1

Trials

1 trial available for etodolac and Condition, Preneoplastic

ArticleYear
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
    International journal of cancer, 2010, Mar-15, Volume: 126, Issue:6

    Topics: Aged; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Follow-Up Studies; Gastritis; Helicobacter pylo

2010

Other Studies

2 other studies available for etodolac and Condition, Preneoplastic

ArticleYear
Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2004, Volume: 56, Issue:3

    Topics: 4-Nitroquinoline-1-oxide; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinogens; Carci

2004
Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
    Biochemical and biophysical research communications, 2005, Aug-26, Volume: 334, Issue:2

    Topics: Animals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Etodolac; Gerbillinae; Helicob

2005